Newron Pharmaceuticals - Operational flexibility with new/updated financing
Newron Pharmaceuticals has announced new arrangements that offer the company improved operational flexibility. We estimate a pro forma gross cash...
412 Views
Newron Pharmaceuticals - TRS data green-lights evenamide Phase III plans
Newron has announced positive 12-month data from its Phase II extension trial (study 015) assessing evenamide in 161 patients with...
433 Views
Newron Pharmaceuticals - Key Evenamide readouts on the horizon
Newron is a Swiss Stock Exchange SIX-listed (NWRN) biopharmaceutical company focused on developing novel medicines for diseases of the central...
258 Views
Newron Pharmaceuticals - Positive readout highlights evenamide potential
Newron has announced encouraging interim six-month data from its Phase II trial (study 014/015) of evenamide in 161 patients with...
212 Views
Newron Pharmaceuticals - Crucial upcoming datasets for evenamide
Newron has released its H123 results and presented an overview of its upcoming clinical activities assessing evenamide as a potential treatment for...
113 Views